

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

Gabelli Healthcare & WellnessRx Trust
Form N-Q
May 30, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF
REGISTERED MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number 811-22021

The Gabelli Healthcare & Wellness(Rx) Trust

(Exact name of registrant as specified in charter)

One Corporate Center
Rye, New York 10580-1422

(Address of principal executive offices) (Zip code)

Agnes Mullady
Gabelli Funds, LLC
One Corporate Center
Rye, New York 10580-1422

(Name and address of agent for service)

Registrant's telephone number, including area code: 1-800-422-3554

Date of fiscal year end: December 31

Date of reporting period: March 31, 2008

Form N-Q is to be used by management investment companies, other than small business investment companies registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than 60 days after the close of the first and third fiscal quarters, pursuant to rule 30b1-5 under the Investment Company Act of 1940 (17 CFR 270.30b1-5). The Commission may use the information provided on Form N-Q in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-Q, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-Q unless the Form displays a currently valid Office of Management and Budget ("OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

ITEM 1. SCHEDULE OF INVESTMENTS.

The Schedule(s) of Investments is attached herewith.

[LOGO]

THE GABELLI
HEALTHCARE &
WELLNESS (RX) TRUST

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST

First Quarter Report
March 31, 2008

TO OUR SHAREHOLDERS,

The Gabelli Healthcare & Wellness(Rx) Trust's (the "Fund") net asset value ("NAV") total return declined 5.5% for the first quarter of 2008, compared with declines of 9.4%, 11.5%, and 2.2% for the Standard & Poor's ("S&P") 500 Index, the S&P 500 Health Care Index, and the S&P 500 Consumer Staples Index, respectively. The price of the Fund's publicly traded shares declined 6.1% during the first quarter. On March 31, 2008, the Fund's NAV per share was \$7.59, while the price of the publicly traded shares closed at \$6.66 on the New York Stock Exchange.

Enclosed is the investment portfolio as of March 31, 2008.

COMPARATIVE RESULTS

RETURNS THROUGH MARCH 31, 2008 (a)

| | Quarter | Since Inception (06/28/07) |
|--|---------|----------------------------------|
| | ----- | ----- |
| GABELLI HEALTHCARE & WELLNESS (RX) TRUST | | |
| NAV TOTAL RETURN (b) | (5.48)% | (4.53)% |
| INVESTMENT TOTAL RETURN (c) | (6.06) | (16.16) |
| S&P 500 Index | (9.44) | (10.82) (d) |
| S&P 500 Health Care Index | (11.52) | (10.99) |
| S&P 500 Consumer Staples Index | (2.21) | 6.36 |

(a) RETURNS REPRESENT PAST PERFORMANCE AND DO NOT GUARANTEE FUTURE RESULTS. INVESTMENT RETURNS AND THE PRINCIPAL VALUE OF AN INVESTMENT WILL FLUCTUATE. WHEN SHARES ARE SOLD, THEY MAY BE WORTH MORE OR LESS THAN THEIR ORIGINAL COST. CURRENT PERFORMANCE MAY BE LOWER OR HIGHER THAN THE PERFORMANCE DATA PRESENTED. VISIT WWW.GABELLI.COM FOR PERFORMANCE INFORMATION AS OF THE MOST RECENT MONTH END. PERFORMANCE RETURNS FOR PERIODS LESS THAN ONE YEAR ARE NOT ANNUALIZED. INVESTORS SHOULD CAREFULLY CONSIDER THE INVESTMENT OBJECTIVES, RISKS, CHARGES, AND EXPENSES OF THE FUND BEFORE INVESTING. THE S&P 500, S&P 500 HEALTH CARE, AND S&P 500 CONSUMER STAPLES INDICES ARE UNMANAGED INDICATORS OF STOCK MARKET PERFORMANCE. DIVIDENDS ARE CONSIDERED REINVESTED. YOU CANNOT INVEST DIRECTLY IN AN INDEX.

(b) TOTAL RETURNS AND AVERAGE ANNUAL RETURNS REFLECT CHANGES IN THE NAV PER SHARE AND REINVESTMENT OF DISTRIBUTIONS AT NAV ON THE EX-DIVIDEND DATE AND ARE NET OF EXPENSES. SINCE INCEPTION RETURN IS BASED ON AN INITIAL NAV OF \$8.00.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

- (c) TOTAL RETURNS AND AVERAGE ANNUAL RETURNS REFLECT CHANGES IN CLOSING MARKET VALUES ON THE NEW YORK STOCK EXCHANGE AND REINVESTMENT OF DISTRIBUTIONS. SINCE INCEPTION RETURN IS BASED ON AN INITIAL OFFERING PRICE OF \$8.00.
- (d) FROM JUNE 30, 2007, THE DATE CLOSEST TO THE FUND'S INCEPTION FOR WHICH DATA IS AVAILABLE.

We have separated the portfolio managers' commentary from the financial statements and investment portfolio due to corporate governance regulations stipulated by the Sarbanes-Oxley Act of 2002. We have done this to ensure that the content of the portfolio managers' commentary is unrestricted. The financial statements and investment portfolio are mailed separately from the commentary. Both the commentary and the financial statements, including the portfolio of investments, will be available on our website at www.gabelli.com.

THE GABELLI HEALTHCARE & WELLNESS(RX) TRUST
 SCHEDULE OF INVESTMENTS
 MARCH 31, 2008 (UNAUDITED)

SHARES

| | |
|---------|--------------------------------------|
| | COMMON STOCKS -- 76.6% |
| | AGRICULTURE -- 0.6% |
| 10,000 | UAP Holding Corp. |
| | BEVERAGES -- 5.8% |
| 20,000 | Cadbury Schweppes plc, ADR |
| 10,000 | Hansen Natural Corp.+ |
| 60,000 | ITO EN Ltd. |
| 7,500 | ITO EN Ltd., Preference |
| 10,000 | PepsiCo Inc. |
| 3,000 | Sapporo Holdings Ltd. |
| 10,000 | The Coca-Cola Co. |
| | BIOTECHNOLOGY -- 4.8% |
| 25,000 | 3SBio Inc., ADR+ |
| 200 | Alnylam Pharmaceuticals Inc.+ |
| 200 | Arena Pharmaceuticals Inc.+ |
| 40,000 | Array Biopharma Inc.+ |
| 8,000 | Cephalon Inc.+ |
| 11,500 | Crucell NV, ADR+ |
| 60,000 | CytRx Corp.+ |
| 450,000 | Encysive Pharmaceuticals Inc.+ |
| 6,000 | Gilead Sciences Inc.+ |
| 20,000 | Monogram Biosciences Inc.+ |
| 6,000 | Myriad Genetics Inc.+ |
| 5,000 | Omrix Biopharmaceuticals Inc.+ |
| 2,993 | RXi Pharmaceuticals Corp.+ |
| 20,000 | Vanda Pharmaceuticals Inc.+ |

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

| | |
|---------|--|
| | CHEMICALS -- 0.8% |
| 12,000 | International Flavors & Fragrances Inc. |
| | FOOD -- 25.8% |
| 40,000 | Campbell Soup Co. |
| 52,000 | Dean Foods Co.+ |
| 100,000 | Del Monte Foods Co. |
| 22,000 | Flowers Foods Inc. |
| 20,000 | General Mills Inc. |
| 22,000 | Groupe Danone |
| 2,000 | Groupe Danone, ADR |
| 12,000 | H.J. Heinz Co. |
| 27,000 | Hain Celestial Group Inc.+ |
| 15,000 | Kellogg Co. |
| 16,000 | Kerry Group plc, Cl. A |
| 40,000 | Kikkoman Corp. |
| 50,000 | Lifeway Foods Inc.+ |
| 100,000 | Meiji Seika Kaisha Ltd. |
| 15,000 | Morinaga Milk Industry Co. Ltd. |

SHARES

| | |
|---------|---|
| 3,900 | Nestle SA |
| 200 | Nestle SA, ADR |
| 5,000 | Parmalat SpA |
| 15,000 | Rock Field Co. Ltd. |
| 43,500 | Smart Balance Inc.+ |
| 15,000 | The J.M. Smucker Co. |
| 7,300 | Wimm-Bill-Dann Foods OJSC, ADR |
| 40,000 | YAKULT HONSHA Co. Ltd. |
| | FOOD AND STAPLES RETAILING -- 9.7% |
| 6,000 | Costco Wholesale Corp. |
| 34,000 | CVS Caremark Corp. |
| 12,000 | SUPERVALU Inc. |
| 37,777 | The Great Atlantic & Pacific Tea Co. Inc.+ |
| 500 | Village Super Market Inc., Cl. A |
| 10,000 | Wal-Mart Stores Inc. |
| 22,000 | Walgreen Co. |
| 52,000 | Whole Foods Market Inc. |
| | HEALTH CARE EQUIPMENT AND SUPPLIES -- 14.1% |
| 5,000 | ABIOMED Inc.+ |
| 11,000 | Advanced Medical Optics Inc.+ |
| 5,000 | Align Technology Inc.+ |
| 175,000 | AMDL Inc.+ (a) |
| 40,000 | AngioDynamics Inc.+ |
| 16,000 | Boston Scientific Corp.+ |
| 10,000 | Covidien Ltd. |
| 32,000 | Cutera Inc.+ |
| 68,000 | E-Z-EM-Inc.+ |
| 21,200 | ev3 Inc.+ |
| 27,000 | Greatbatch Inc.+ |
| 8,500 | Inverness Medical Innovations Inc.+ |

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

| | |
|---------|---|
| 12,200 | Kinetic Concepts Inc.+ |
| 15,000 | Medical Action Industries Inc.+ |
| 9,000 | Medtronic Inc. |
| 4,200 | Mentor Corp. |
| 30,000 | Micrus Endovascular Corp.+ |
| 3,000 | Orthofix International NV+ |
| 200,000 | Specialized Health Products International Inc.+ |
| 14,000 | St. Jude Medical Inc.+ |
| 30,000 | Thoratec Corp.+ |
| 85,000 | Vascular Solutions Inc.+ |
| 9,000 | Zimmer Holdings Inc.+ |

See accompanying notes to schedule of investments.

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
 SCHEDULE OF INVESTMENTS (CONTINUED)
 MARCH 31, 2008 (UNAUDITED)

SHARES

| | |
|---------|--|
| | COMMON STOCKS (CONTINUED) |
| | HEALTH CARE PROVIDERS AND SERVICES -- 8.5% |
| 14,000 | Aetna Inc. |
| 11,000 | Amedisys Inc.+ |
| 30,000 | American Dental Partners Inc.+ |
| 7,000 | AmerisourceBergen Corp. |
| 8,000 | Cardinal Health Inc. |
| 3,500 | Healthways Inc.+ |
| 45,000 | HLTH Corp.+ |
| 150,000 | I-Trax Inc.+ |
| 12,000 | IMS Health Inc. |
| 6,000 | MedAssets Inc.+ |
| 30,000 | NightHawk Radiology Holdings Inc.+ |
| 20,000 | Omnicare Inc. |
| 1,000 | Owens & Minor Inc. |
| 15,000 | PSS World Medical Inc.+ |
| 24,200 | UnitedHealth Group Inc. |
| | PHARMACEUTICALS -- 6.5% |
| 11,000 | Abbott Laboratories |
| 7,500 | Alpharma Inc., Cl. A+ |
| 14,000 | Barr Pharmaceuticals Inc.+ |
| 16,800 | Inspire Pharmaceuticals Inc.+ |
| 21,000 | Johnson & Johnson |
| 20,000 | K-V Pharmaceutical Co., Cl. A+ |
| 18,000 | Matrixx Initiatives Inc.+ |
| 13,000 | Merck & Co. Inc. |

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

2,200 Pain Therapeutics Inc.+

TOTAL COMMON STOCKS

WARRANTS -- 0.2%

HEALTH CARE EQUIPMENT AND SUPPLIES -- 0.2%

80,907 AMDL Inc., expire 03/05/11+ (a)

PRINCIPAL
AMOUNT

U.S. GOVERNMENT OBLIGATIONS -- 23.2%

\$ 15,027,000 U.S. Treasury Bills, 1.213% to 3.065%+, 04/03/08 to 09/04/08

TOTAL INVESTMENTS -- 100.0%

(Cost \$68,535,715)

Aggregate book cost

Gross unrealized appreciation

Gross unrealized depreciation

Net unrealized appreciation/depreciation

(a) Security fair valued under procedures established by the Board of Trustees. The procedures may include reviewing available financial information about the company and reviewing the valuation of comparable securities and other factors on a regular basis. At March 31, 2008, the market value of fair valued securities amounted to \$694,514 or 1.08% of total investments.

+ Non-income producing security.

++ Represents annualized yield at date of purchase.

ADR American Depositary Receipt

| GEOGRAPHIC DIVERSIFICATION | % OF MARKET VALUE | MARKET VALUE |
|----------------------------|-------------------------|-----------------|
| North America | 83.3% | \$ 53,685,567 |
| Europe | 9.8 | 6,305,144 |
| Japan | 5.7 | 3,694,272 |
| Latin America | 1.2 | 780,310 |
| Total Investments | 100.0% | \$ 64,465,293 |

See accompanying notes to schedule of investments.

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
NOTES TO SCHEDULE OF INVESTMENTS (UNAUDITED)

SECURITY VALUATION. Portfolio securities listed or traded on a nationally recognized securities exchange or traded in the U.S. over-the-counter market for which market quotations are readily available are valued at the last quoted sale price or a market's official closing price as of the close of business on the day the securities are being valued. If there were no sales that day, the security is valued at the average of the closing bid and asked prices or, if there were no asked prices quoted on that day, then the security is valued at the closing bid price on that day. If no bid or asked prices are quoted on such day, the security is valued at the most recently available price or, if the Board of Trustees (the "Board") so determines, by such other method as the Board shall determine in good faith to reflect its fair market value. Portfolio securities traded on more than one national securities exchange or market are valued according to the broadest and most representative market, as determined by Gabelli Funds, LLC, the Adviser.

Portfolio securities primarily traded on a foreign market are generally valued at the preceding closing values of such securities on the relevant market, but may be fair valued pursuant to procedures established by the Board if market conditions change significantly after the close of the foreign market but prior to the close of business on the day the securities are being valued. Debt instruments with remaining maturities of 60 days or less that are not credit impaired are valued at amortized cost, unless the Board determines such amount does not reflect the securities' fair value, in which case these securities will be fair valued as determined by the Board. Debt instruments having a maturity greater than 60 days for which market quotations are readily available are valued at the average of the latest bid and asked prices. If there were no asked prices quoted on such day, the security is valued using the closing bid price. Futures contracts are valued at the closing settlement price of the exchange or board of trade on which the applicable contract is traded.

Securities and assets for which market quotations are not readily available are fair valued as determined by the Board.

ADOPTION OF STATEMENT OF FINANCIAL ACCOUNTING STANDARDS NO. 157 "FAIR VALUE MEASUREMENTS" ("SFAS 157")

On January 1, 2008, the Fund adopted SFAS 157 that clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value, and requires additional disclosures about the use of fair value measurements. The three levels of the fair value hierarchy under SFAS 157 are described below:

- o Level 1 - quoted prices in active markets for identical securities;
- o Level 2 - other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.); and
- o Level 3 - significant unobservable inputs (including the Fund's determinations as to the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of inputs used to value the Fund's net assets as of March 31, 2008 is as follows:

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

| VALUATION INPUTS | INVESTMENTS IN SECURITIES (MARKET VALUE) |
|---|--|
| Level 1 - Quoted Prices | \$48,783,865 |
| Level 2 - Other Significant Observable Inputs | 15,681,428 |
| Total | \$64,465,293 |

4

THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
AND YOUR PERSONAL PRIVACY

WHO ARE WE?

The Gabelli Healthcare & Wellness(Rx) Trust (the "Fund") is a closed-end management investment company registered with the Securities and Exchange Commission under the Investment Company Act of 1940. We are managed by Gabelli Funds, LLC, which is affiliated with GAMCO Investors, Inc. GAMCO Investors, Inc. is a publicly held company that has subsidiaries that provide investment advisory or brokerage services for a variety of clients.

WHAT KIND OF NON-PUBLIC INFORMATION DO WE COLLECT ABOUT YOU IF YOU BECOME A SHAREHOLDER?

When you purchase shares of the Fund on the New York Stock Exchange, you have the option of registering directly with our transfer agent in order, for example, to participate in our dividend reinvestment plan.

- o INFORMATION YOU GIVE US ON YOUR APPLICATION FORM. This could include your name, address, telephone number, social security number, bank account number, and other information.
- o INFORMATION ABOUT YOUR TRANSACTIONS WITH US. This would include information about the shares that you buy or sell; it may also include information about whether you sell or exercise rights that we have issued from time to time. If we hire someone else to provide services--like a transfer agent--we will also have information about the transactions that you conduct through them.

WHAT INFORMATION DO WE DISCLOSE AND TO WHOM DO WE DISCLOSE IT?

We do not disclose any non-public personal information about our customers or former customers to anyone other than our affiliates, our service providers who need to know such information, and as otherwise permitted by law. If you want to find out what the law permits, you can read the privacy rules adopted by the Securities and Exchange Commission. They are in volume 17 of the Code of Federal Regulations, Part 248. The Commission often posts information about its regulations on its website, WWW.SEC.GOV.

WHAT DO WE DO TO PROTECT YOUR PERSONAL INFORMATION?

We restrict access to non-public personal information about you to the people who need to know that information in order to provide services to you or the Fund and to ensure that we are complying with the laws governing the securities business. We maintain physical, electronic, and procedural safeguards to keep your personal information confidential.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

[This Page Intentionally Left Blank.]

TRUSTEES AND OFFICERS
THE GABELLI HEALTHCARE & WELLNESS (RX) TRUST
ONE CORPORATE CENTER, RYE, NY 10580-1422

TRUSTEES

Mario J. Gabelli, CFA
CHAIRMAN & CHIEF EXECUTIVE OFFICER,
GAMCO INVESTORS, INC.

Dr. Thomas E. Bratter
PRESIDENT & FOUNDER, JOHN DEWEY ACADEMY

Anthony J. Colavita
ATTORNEY-AT-LAW,
ANTHONY J. COLAVITA, P.C.

James P. Conn
FORMER MANAGING DIRECTOR &
CHIEF INVESTMENT OFFICER,
FINANCIAL SECURITY ASSURANCE HOLDINGS LTD.

Vincent D. Enright
FORMER SENIOR VICE PRESIDENT &
CHIEF FINANCIAL OFFICER,
KEYSPAN CORP.

Robert C. Kolodny, MD
PHYSICIAN, AUTHOR, AND LECTURER,
GENERAL PARTNER OF KBS PARTNERSHIP

Anthonie C. van Ekris
CHAIRMAN, BALMAC INTERNATIONAL, INC.

Salvatore J. Zizza
CHAIRMAN, ZIZZA & CO., LTD.

OFFICERS

Bruce N. Alpert
SECRETARY

Carter W. Austin
VICE PRESIDENT

Peter D. Goldstein
CHIEF COMPLIANCE OFFICER

Agnes Mullady
PRESIDENT AND TREASURER

David I. Schachter
VICE PRESIDENT

Adam E. Tokar
ASSISTANT VICE PRESIDENT & OMBUDSMAN

INVESTMENT ADVISER
Gabelli Funds, LLC
One Corporate Center
Rye, New York 10580-1422

CUSTODIAN
Mellon Trust of New England, N.A.

COUNSEL
Willkie Farr & Gallagher LLP

TRANSFER AGENT AND REGISTRAR
Computershare Trust Company, N.A.

STOCK EXCHANGE LISTING

Common

NYSE-Symbol:

GRX

Shares Outstanding:

8,474,459

The Net Asset Value per share appears in the Publicly Traded Funds column, under the heading "Specialized Equity Funds," in Monday's The Wall Street Journal. It is also listed in Barron's Mutual Funds/Closed End Funds section under the heading "Specialized Equity Funds."

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

The Net Asset Value per share may be obtained each day by calling (914) 921-5070 or visiting www.gabelli.com.

For general information about the Gabelli Funds, call 800-GABELLI (800-422-3554), fax us at 914-921-5118, visit Gabelli Funds' Internet homepage at: WWW.GABELLI.COM, or e-mail us at: closedend@gabelli.com

Notice is hereby given in accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may, from time to time, purchase its common shares in the open market when the Fund's shares are trading at a discount of 10% or more from the net asset value of the shares.

THE GABELLI HEALTHCARE &
WELLNESS(RX) TRUST
ONE CORPORATE CENTER
RYE, NY 10580-1422
(914) 921-5070
WWW.GABELLI.COM

FIRST QUARTER REPORT
MARCH 31, 2008

GRX Q1/2008

ITEM 2. CONTROLS AND PROCEDURES.

- (a) The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act") (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).
- (b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d))) that occurred during the registrant's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

ITEM 3. EXHIBITS.

Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto.

Edgar Filing: Gabelli Healthcare & WellnessRx Trust - Form N-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) The Gabelli Healthcare & Wellness(Rx) Trust

By (Signature and Title)* /s/ Agnes Mullady

Agnes Mullady, Principal Executive Officer and
Principal Financial Officer

Date May 29, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)* /s/ Agnes Mullady

Agnes Mullady, Principal Executive Officer and
Principal Financial Officer

Date May 29, 2008

* Print the name and title of each signing officer under his or her signature.